Physician profile
Gary Kirsh
NPI 1770525073
$73,421.25
in general payments reported to CMS, 2019-2025
31 companies · $807 in 2025
The $807 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $31K · 2021: $7,595 · 2022: $1,169 · 2023: $1,132 · 2024: $1,199 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,138.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $21,220.00 | 2019-2025 | |
| Tolmar Pharmaceuticals, INC. | $17,528.07 | 2020 | |
| Dendreon Pharmaceuticals LLC | $10,319.14 | 2019-2024 | Provenge |
| Janssen Biotech, INC. | $7,779.36 | 2019-2025 | Erleada |
| Integra Gpo, LLC | $5,440.91 | 2019 | |
| Janssen Scientific Affairs, LLC | $4,300.85 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $2,003.62 | 2020-2021 | |
| Teleflex LLC | $689.17 | 2021-2025 | Urolift |
| Urogen Pharma, INC. | $461.93 | 2021-2023 | Jelmyto |
| Coloplast Corp | $460.12 | 2019-2023 | Speedicath, Titan |
| Abbvie INC. | $450.06 | 2019-2024 | |
| Calyxo, INC. | $365.88 | 2025 | Cvac Aspiration System |
| Neotract INC. | $335.53 | 2019 | |
| Myriad Genetic Laboratories, INC. | $252.01 | 2021-2023 | Prolaris |
| Axonics, INC. | $245.81 | 2020-2023 | Axonics |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Srs Medical Systems, INC. | $240.54 | 2022-2024 | Urocuff-Dc Disposable, Single, Ct3000 Pro Base Unit |
| Boston Scientific Corporation | $235.43 | 2019-2024 | Lithovue |
| Intrinsiq Specialty Solutions, INC. | $196.54 | 2022 | |
| Pfizer INC. | $154.46 | 2019-2022 | |
| Clovis Oncology, INC. | $138.11 | 2021 | |
| Bioprotect Medical, INC. | $116.56 | 2024 | Bioprotect Balloon Implant System |
| Astellas Pharma US INC | $85.71 | 2019-2021 | |
| Foundation Medicine, INC. | $80.00 | 2022 | |
| Myovant Sciences INC. | $79.72 | 2022 | |
| Palette Life Sciences, INC. | $65.00 | 2022 | |
| Sumitomo Pharma America, INC. | $62.50 | 2023-2024 | Orgovyx |
| Novartis Pharmaceuticals Corporation | $41.12 | 2022 | |
| Asd Specialty Healthcare, LLC | $28.72 | 2022 | |
| Avyxa Pharma, LLC | $18.60 | 2025 | |
| Endo Pharmaceuticals INC. | $13.56 | 2019 | |
| Ferring Pharmaceuticals INC. | $12.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Kirsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.